Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Sagimet Biosciences Inc. (SGMT : NSDQ)

• Company Description    Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. It involved in developing novel therapeutics targeting dysfunctional metabolic pathways. Sagimet Biosciences Inc. is based in SAN MATEO, Calif. Number of Employees: 16

• Price / Volume Information    Yesterday's Closing Price: $7.09 Daily Weekly Monthly 20 Day Moving Average: 3,615,875 shares Shares Outstanding: 32.58 (millions) Market Capitalization: $231.03 (millions) Beta: 3.60 52 Week High: $11.41 52 Week Low: $3.23 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 20.78% 14.88% 12 Week 20.78% 11.66% Year To Date 19.76% 8.71%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 155 BOVET RD. SUITE 303 - SAN MATEO,CA 94402 USA ph: 650-561-8600 fax: - ir@sagimet.com http://www.sagimet.com

• General Corporate Information    Officers David Happel - President and Chief Executive Officer George Kemble - Chairman Thierry Chauche - Chief Financial Officer Anne Phillips - Director Beth Seidenberg - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 786700104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/12/26 Share - Related Items Shares Outstanding: 32.58 Most Recent Split Date: (:1) Beta: 3.60 Market Capitalization: $231.03 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.26 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.15 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.25 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 41.07% vs. Previous Quarter: -13.79% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -37.57 12/31/25 - -40.85 09/30/25 - -42.39 ROA 03/31/26 - -35.52 12/31/25 - -38.63 09/30/25 - -40.31 Current Ratio 03/31/26 - 20.33 12/31/25 - 22.82 09/30/25 - 13.06 Quick Ratio 03/31/26 - 20.34 12/31/25 - 22.82 09/30/25 - 13.06 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 3.14 12/31/25 - 3.42 09/30/25 - 3.67 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©